Cell-free DNA as a Plausible Biomarker of Chronic Kidney Disease

References

• GBD 2013 Mortality and Causes of Death Collaborators . Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet385(9963), 117–171 (2015).
   PubMed Web of Science ®Google Scholar
• Fletcher BR , DameryS , AiyegbusiOLet al. Symptom burden and health-related quality of life in chronic kidney disease: a global systematic review and meta-analysis. PLOS Med.19(4), e1003954 (2022).
   PubMed Web of Science ®Google Scholar
• George C , MogueoA , OkpechiIet al. Chronic kidney disease in low-income to middle-income countries: the case for increased screening. BMJ Glob. Health2(2), e000256 (2017).
   PubMed Web of Science ®Google Scholar
• Glassock R , WarnockD , DelanayeP. The global burden of chronic kidney disease: estimates, variability and pitfalls. Nat. Rev. Nephrol.13, 104–114 (2017).
   PubMed Web of Science ®Google Scholar
• Jha V , Garcia-GarciaG , IsekiKet al. Chronic kidney disease: global dimension and perspectives. Lancet382, 260–272 (2013).
   PubMed Web of Science ®Google Scholar
• Lozano R , NaghaviM , ForemanKet al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet380(9859), 2095–2128 (2012).
   PubMed Web of Science ®Google Scholar
• Murton M , Goff-LeggettD , BobrowskaAet al. Burden of chronic kidney disease by KDIGO categories of glomerular filtration rate and albuminuria: a systematic review. Adv. Ther.38(1), 180–200 (2021).
   PubMed Web of Science ®Google Scholar
• Xie Y , BoweB , MokdadAHet al. Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. Kidney Int.94(3), 567–581 (2018).
   PubMed Web of Science ®Google Scholar
• Thurlow JS , JoshiM , YanGet al. Global epidemiology of end-stage kidney disease and disparities in kidney replacement therapy. Am. J. Nephrol.52(2), 98–107 (2021).
   PubMed Web of Science ®Google Scholar
• Thomas MC , CooperME , ZimmetP. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat. Rev. Nephrol.12(2), 73–81 (2016).
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K , JafarTH , NitschDet al. Chronic kidney disease. Lancet398(10302), 786–802 (2021).
   PubMed Web of Science ®Google Scholar
• Major RW , ChengMRI , GrantRAet al. Cardiovascular disease risk factors in chronic kidney disease: a systematic review and meta-analysis. PLOS ONE13(3), e0192895 (2018).
   PubMed Web of Science ®Google Scholar
• Műzes G , BohusnéBarta B , SzabóOet al. Cell-Free DNA in the pathogenesis and therapy of non-infectious inflammations and tumors. Biomedicines10(11), 2853 (2022).
   PubMed Web of Science ®Google Scholar
• Drag MH , KilpeläinenTO. Cell-free DNA and RNA-measurement and applications in clinical diagnostics with focus on metabolic disorders. Physiol. Genomics53(1), 33–46 (2021).
   PubMed Web of Science ®Google Scholar
• Heitzer E , AuingerL , SpeicherMR. Cell-free DNA and apoptosis: how dead cells inform about the living. Trends Mol. Med.26(5), 519–528 (2020).
   PubMed Web of Science ®Google Scholar
• Jing Q , LeungCHC , WuAR. Cell-free DNA as biomarker for sepsis by integration of microbial and host information. Clin. Chem.68(9), 1184–1195 (2022).
   PubMed Web of Science ®Google Scholar
• Leffler J , CiacmaK , GullstrandBet al. A subset of patients with systemic lupus erythematosus fails to degrade DNA from multiple clinically relevant sources. Arthritis Res. Ther.17(1), 205 (2015).
   PubMedGoogle Scholar
• Duvvuri B , LoodC. Cell-free DNA as a biomarker in autoimmune rheumatic diseases. Front. Immunol.10, 502 (2019).
   PubMed Web of Science ®Google Scholar
• Ulrich BC , PaweletzCP. Cell-free DNA in oncology: gearing up for clinic. Ann. Lab. Med.38(1), 1–8 (2018).
   PubMed Web of Science ®Google Scholar
• Tsuji N , Agbor-EnohS. Cell-free DNA beyond a biomarker for rejection: biological trigger of tissue injury and potential therapeutics. J. Heart Lung Transplant.40(6), 405–413 (2021).
   PubMed Web of Science ®Google Scholar
• Li X , HuR , LuoTet al. Serum cell-free DNA and progression of diabetic kidney disease: a prospective study. BMJ Open Diabetes Res. Care8(1), e001078 (2020).
   PubMed Web of Science ®Google Scholar
• Einbinder Y , ShnaiderA , GhanayemKet al. Elevated circulating cell-free DNA in hemodialysis-treated patients is associated with increased mortality. Am. J. Nephrol.51(11), 852–860 (2020).
   PubMed Web of Science ®Google Scholar
• Lo YMD , HanDSC , JiangPet al. Epigenetics, fragmentomics, and topology of cell-free DNA in liquid biopsies. Science372(6538), eaaw3616 (2021).
   PubMed Web of Science ®Google Scholar
• Meddeb R , DacheZAA , ThezenasSet al. Quantifying circulating cell-free DNA in humans. Sci. Rep.9, 5220 (2019).
   PubMedGoogle Scholar
• Bronkhorst AJ , UngererV , DiehlFet al. Towards systematic nomenclature for cell-free DNA. Hum. Genet.140(4), 565–578 (2021).
   PubMed Web of Science ®Google Scholar
• Thierry AR , ElMessaoudi S , GahanPBet al. Origins, structures, and functions of circulating DNA in oncology. Cancer Metastasis Rev.35, 347–376 (2016).
   PubMed Web of Science ®Google Scholar
• Snyder MW , KircherM , HillAJet al. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell164, 57–68 (2016).
   PubMed Web of Science ®Google Scholar
• Diaz LA , BardelliA. Liquid biopsies: genotyping circulating tumor DNA. J. Clin. Oncol.32, 579–586 (2014).
   PubMed Web of Science ®Google Scholar
• Kustanovich A , SchwartzR , PeretzTet al. Life and death of circulating cell-free DNA. Cancer Biol. Ther.20(8), 1057–1067 (2019).
   PubMed Web of Science ®Google Scholar
• García Moreira V , dela Cera Martínez T , GagoGonzález Eet al. Increase in and clearance of cell-free plasma DNA in hemodialysis quantified by real-time PCR. Clin. Chem. Lab. Med.44(12), 1410–1415 (2006).
   PubMed Web of Science ®Google Scholar
• Mouliere F , ChandranandaD , PiskorzAMet al. Enhanced detection of circulating tumor DNA by fragment size analysis. Sci. Transl. Med.10(466), eaat4921 (2018).
   PubMed Web of Science ®Google Scholar
• Jahr S , HentzeH , EnglischSet al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res.61(4), 1659–1665 (2001).
   PubMed Web of Science ®Google Scholar
• Beck J , OellerichM , SchulzUet al. Donor-derived cell-free DNA Is a novel universal biomarker for allograft rejection in solid organ transplantation. Transplant. Proc.47(8), 2400–2403 (2015).
   PubMed Web of Science ®Google Scholar
• Bianchi DW , ChiuRWK. Sequencing of circulating cell-free DNA during pregnancy. N. Engl. J. Med.379(5), 464–473 (2018).
   PubMed Web of Science ®Google Scholar
• Arosemena M , MeahFA , MatherKJet al. Cell-free DNA fragments as biomarkers of islet β-cell death in obesity and type 2 diabetes. Int. J. Mol. Sci.22(4), 2151 (2021).
   PubMed Web of Science ®Google Scholar
• Syed F , TerseySA , TuratsinzeJVet al. Circulating unmethylated CHTOP and INS DNA fragments provide evidence of possible islet cell death in youth with obesity and diabetes. Clin. Epigenetics12(1), 116 (2020).
   PubMed Web of Science ®Google Scholar
• Liu Y , TanQ , LiuF. Differentially methylated circulating DNA: a novel biomarker to monitor beta cell death. J. Diabetes Complications32(3), 349–353 (2018).
   PubMed Web of Science ®Google Scholar
• Jaramillo-Morales J , KorucuB , PikeMMet al. Effects of caloric restriction and aerobic exercise on circulating cell-free mitochondrial DNA in patients with moderate to severe chronic kidney disease. Am. J. Physiol. Renal Physiol.322(1), F68–F75 (2022).
   PubMed Web of Science ®Google Scholar
• Park SS , JeongH , AndreazzaAC. Circulating cell-free mitochondrial DNA in brain health and disease: a systematic review and meta-analysis. World J. Biol. Psychiatry23(2), 87–102 (2022).
   PubMed Web of Science ®Google Scholar
• Zawrotniak M , Rapala-KozikM. Neutrophil extracellular traps (NETs) – formation and implications. Acta Biochim. Pol.60(3), 277–284 (2013).
   PubMed Web of Science ®Google Scholar
• Frangou E , VassilopoulosD , BoletisJet al. An emerging role of neutrophils and NETosis in chronic inflammation and fibrosis in systemic lupus erythematosus (SLE) and ANCA-associated vasculitides (AAV): implications for the pathogenesis and treatment. Autoimmun. Rev.18(8), 751–760 (2019).
   PubMed Web of Science ®Google Scholar
• Brodbeck K , SchickS , BayerBet al. Biological variability of cell-free DNA in healthy females at rest within a short time course. Int. J. Legal. Med.134(3), 911–919 (2020).
   PubMed Web of Science ®Google Scholar
• Alborelli I , GeneraliD , JermannPet al. Cell-free DNA analysis in healthy individuals by next-generation sequencing: a proof of concept and technical validation study. Cell Death Dis.10(7), 534 (2019).
   PubMedGoogle Scholar
• Haller N , TomaskovicA , StögglTet al. Feasibility of cell-free DNA measurement from the earlobe during physiological exercise testing. Diagnostics (Basel)12(6), 1379 (2022).
   PubMedGoogle Scholar
• Walczak K , StawskiR , PerdasEet al. Circulating cell free DNA response to exhaustive exercise in average trained men with type I diabetes mellitus. Sci. Rep.11(1), 4639 (2021).
   PubMed Web of Science ®Google Scholar
• Nie S , LuJ , WangL , GaoM. Pro-inflammatory role of cell-free mitochondrial DNA in cardiovascular diseases. IUBMB Life72(9), 1879–1890 (2020).
   PubMed Web of Science ®Google Scholar
• Berezina TA , KopytsyaMP , PetyuninaOVet al. Lower circulating cell-free mitochondrial DNA is associated with heart failure in type 2 diabetes mellitus patients. Cardiogenetics13(1), 15–30 (2023).
   Web of Science ®Google Scholar
• Zhang Q , HeX , LingJet al. Association between circulating cell-free DNA level at admission and the risk of heart failure incidence in acute myocardial infarction patients. DNA Cell Biol.41(8), 742–749 (2022).
   PubMed Web of Science ®Google Scholar
• Dias S , WillmerT , AdamS , PheifferC. The role of maternal DNA methylation in pregnancies complicated by gestational diabetes. Front. Clin. Diabetes Healthc.3, 982665 (2022).
   PubMedGoogle Scholar
• Del Vecchio G , LiQ , LiWet al. Cell-free DNA methylation and transcriptomic signature prediction of pregnancies with adverse outcomes. Epigenetics16(6), 642–661 (2021).
   PubMed Web of Science ®Google Scholar
• Hopkins MK , KoelperN , BenderWet al. Association between cell-free DNA fetal fraction and gestational diabetes. Prenat. Diagn.40(6), 724–727 (2020).
   PubMed Web of Science ®Google Scholar
• Linares-Pineda TM , Gutiérrez-RepisoC , Peña-MonteroNet al. Higher β cell death in pregnant women, measured by DNA methylation patterns of cell-free DNA, compared to new-onset type 1 and type 2 diabetes subjects: a cross-sectional study. Diabetol. Metab. Syndr.15(1), 115 (2023).
   PubMed Web of Science ®Google Scholar
• Lappas M , GeorgiouHM , WillcoxJCet al. Postpartum circulating cell-free insulin DNA levels are higher in women with previous gestational diabetes mellitus who develop type 2 diabetes in later life. J. Diabetes Res.2019, 3264184 (2019).
   PubMed Web of Science ®Google Scholar
• El Tarhouny SA , HadhoudKM , EbrahemMMet al. Assessment of cell-free DNA with microvascular complication of type II diabetes mellitus, using PCR and ELISA. Nucleosides Nucleotides Nucleic Acids29, 228–236 (2010).
   PubMed Web of Science ®Google Scholar
• Hu J , WangY , XiangXet al. Serum bisphenol A as a predictor of chronic kidney disease progression in primary hypertension: a 6-year prospective study. J. Hypertens.34, 332–337 (2016).
   PubMed Web of Science ®Google Scholar
• Chang CC , ChiuPF , WuCLet al. Urinary cell-free mitochondrial and nuclear deoxyribonucleic acid correlates with the prognosis of chronic kidney diseases. BMC Nephrol.20(1), 391 (2019).
   PubMed Web of Science ®Google Scholar
• McGuire AL , UrosevicN , ChanDTet al. The impact of chronic kidney disease and short-term treatment with rosiglitazone on plasma cell-free DNA levels. PPAR Res.2014, 643189 (2014).
   PubMed Web of Science ®Google Scholar
• Zhang Y , ZhaoY , WenSet al. Associations of mitochondrial haplogroups and mitochondrial DNA copy numbers with end-stage renal disease in a Han population. Mitochondrial DNA A: DNA Mapp. Seq. Anal.28(5), 725–731 (2017).
   Google Scholar
• Ozkaya O , BekK , BedirAet al. Plasma cell-free DNA levels in children on peritoneal dialysis. Nephron Clin. Pract.113(4), c258–c261 (2009).
   PubMedGoogle Scholar
• Korabecna M , OpatrnaS , WirthJet al. Cell-free plasma DNA during peritoneal dialysis and hemodialysis and in patients with chronic kidney disease. Ann. NY Acad. Sci.1137, 296–301 (2008).
   PubMed Web of Science ®Google Scholar
• Opatrna S , WirthJ , KorabecnaM , SefrnaF. Cell-free plasma DNA during hemodialysis. Ren. Fail.31(6), 475–480 (2009).
   PubMed Web of Science ®Google Scholar
• Cichota LC , BochiGV , TatschEet al. Circulating double-stranded DNA in plasma of hemodialysis patients and its association with iron stores. Clin. Lab.61(8), 985–990 (2015).
   PubMed Web of Science ®Google Scholar
• Tovbin D , NovackV , WiessmanMPet al. Circulating cell-free DNA in hemodialysis patients predicts mortality. Nephrol. Dial. Transplant.27(10), 3929–3935 (2012).
   PubMed Web of Science ®Google Scholar
• Atamaniuk J , KopeckyC , SkoupySet al. Apoptotic cell-free DNA promotes inflammation in haemodialysis patients. Nephrol. Dial. Transplant.27(3), 902–905 (2012).
   PubMed Web of Science ®Google Scholar
• Kim K , JungSW , ChoWHet al. Associations between cell-free mitochondrial DNA and inflammation, and their clinical implications for patients on hemodialysis: a prospective multicenter cohort study. Blood Purif.50(2), 214–221 (2021).
   PubMed Web of Science ®Google Scholar
• Fan Z , GuoY , ZhongXY. Circulating Cell-free mitochondrial DNA: a potential blood-based biomarker for sarcopenia in patients undergoing maintenance hemodialysis. Med. Sci. Monit.28, e934679 (2022).
   PubMed Web of Science ®Google Scholar
• Jeong JC , KimJE , GuJYet al. Significance of the DNA–histone complex level as a predictor of major adverse cardiovascular events in hemodialysis patients: the effect of uremic toxin on DNA–histone complex formation. Blood Purif.41(1–3), 64–71 (2016).
   PubMed Web of Science ®Google Scholar
• Gaál Kovalčíková A , Janovičovἠ, HodosyJet al. Extracellular DNA concentrations in various aetiologies of acute kidney injury. Sci. Rep.12(1), 16812 (2022).
   PubMed Web of Science ®Google Scholar
• Gisterå A , HanssonGK. The immunology of atherosclerosis. Nat. Rev. Nephrol.13(6), 368–380 (2017).
   PubMed Web of Science ®Google Scholar
• Goligorsky MS . NET formation in dialysis: a valuable, albeit mysterious and enticing predictor of mortality. Am. J. Nephrol.51(11), 849–851 (2020).
   PubMed Web of Science ®Google Scholar
• Kant S , BrennanDC. Donor derived cell free DNA in kidney transplantation: the circa 2020–2021 update. Transpl. Int.35, 10448 (2022).
   PubMed Web of Science ®Google Scholar
• Oellerich M , SherwoodK , KeownPet al. Liquid biopsies: donor-derived cell-free DNA for the detection of kidney allograft injury. Nat. Rev. Nephrol.17(9), 591–603 (2021).
   PubMed Web of Science ®Google Scholar
• Oellerich M , BuddeK , OsmanodjaBet al. Donor-derived cell-free DNA for personalized immunosuppression in renal transplantation. Ther. Drug Monit.45(1), 20–25 (2023).
   PubMed Web of Science ®Google Scholar
• Khush KK , PatelJ , PinneySet al. Noninvasive detection of graft injury after heart transplant using donor-derived cell-free DNA: a prospective multicenter study. Am. J. Transplant.19(10), 2889–2899 (2019).
   PubMed Web of Science ®Google Scholar
• Zhang H , ZhengC , LiXet al. Diagnostic performance of donor-derived plasma cell-free DNA fraction for antibody-mediated rejection in post renal transplant recipients: a prospective observational study. Front. Immunol.11, 342 (2020).
   PubMed Web of Science ®Google Scholar
• Bloom RD , BrombergJS , PoggioEDet al.; Circulating Donor-Derived Cell-Free DNA in Blood for Diagnosing Active Rejection in Kidney Transplant Recipients (DART) Study Investigators. Cell-free DNA and active rejection in kidney allografts. J. Am. Soc. Nephrol.28(7), 2221–2232 (2017).
   PubMed Web of Science ®Google Scholar
• Oellerich M , ShipkovaM , AsendorfTet al. Absolute quantification of donor-derived cell-free DNA as a marker of rejection and graft injury in kidney transplantation: results from a prospective observational study. Am. J. Transplant.19(11), 3087–3099 (2019).
   PubMed Web of Science ®Google Scholar
• Mayer KA , DobererK , TillgrenAet al. Diagnostic value of donor-derived cell-free DNA to predict antibody-mediated rejection in donor-specific antibody-positive renal allograft recipients. Transpl. Int.34(9), 1689–1702 (2021).
   PubMed Web of Science ®Google Scholar
• Halloran PF , ReeveJ , Madill-ThomsenKSet al.; Trifecta Investigators. The Trifecta study: comparing plasma levels of donor-derived cell-free DNA with the molecular phenotype of kidney transplant biopsies. J. Am. Soc. Nephrol.33(2), 387–400 (2022).
   PubMed Web of Science ®Google Scholar
• Obrișcă B , ButiuM , SibuleskyLet al. Combining donor-derived cell-free DNA and donor specific antibody testing as non-invasive biomarkers for rejection in kidney transplantation. Sci. Rep.12(1), 15061 (2022).
   PubMed Web of Science ®Google Scholar
• Jordan SC , BunnapradistS , BrombergJSet al. Donor-derived cell-free DNA identifies antibody-mediated rejection in donor specific antibody positive kidney transplant recipients. Transplant. Direct.4(9), e379 (2018).
   PubMedGoogle Scholar
• Butiu M , ObriscaB , SibuleskyLet al. Donor-derived cell-free DNA complements de novo class ii DSA in detecting late alloimmune injury post kidney transplantation. Transplant. Direct.8(2), e1285 (2022).
   PubMed Web of Science ®Google Scholar
• Wolf-Doty TK , MannonRB , PoggioEDet al. Dynamic response of donor-derived cell-free DNA following treatment of acute rejection in kidney allografts. Kidney3602(4), 729–736 (2021).
   PubMedGoogle Scholar
• Gielis EM , LedeganckKJ , DeWinter BYet al. Cell-free DNa: an upcoming biomarker in transplantation. Am. J. Transplant.15(10), 2541–2551 (2015).
   PubMed Web of Science ®Google Scholar
• Shen J , ZhouY , ChenYet al. Dynamics of early post-operative plasma ddcf-DNA levels in kidney transplantation: a single-center pilot study. Transpl. Int.32(2), 184–192 (2019).
   PubMed Web of Science ®Google Scholar
• Osmanodja B , AkifovaA , OellerichMet al. Donor-derived cell-free DNA for kidney allograft surveillance after conversion to belatacept: prospective pilot study. J. Clin. Med.12(6), 2437 (2023).
   PubMed Web of Science ®Google Scholar
• Gielis EM , LedeganckKJ , DendoovenAet al. The use of plasma donor-derived, cell-free DNA to monitor acute rejection after kidney transplantation. Nephrol. Dial. Transplant.35(4), 714–721 (2020).
   PubMed Web of Science ®Google Scholar
• Huang E , MengelM , Clahsen-vanGroningen MC , JacksonAM. Diagnostic potential of minimally invasive biomarkers: a biopsy-centered viewpoint from the Banff Minimally Invasive Diagnostics Working Group. Transplantation107(1), 45–52 (2023).
   PubMed Web of Science ®Google Scholar